Paris Hoey, Naeman Goetz, Kimberley Ryan, Mark Appleyard, Florian Grimpen
{"title":"胶囊内窥镜检查后的小肠癌发病率-澳大利亚数据关联分析。","authors":"Paris Hoey, Naeman Goetz, Kimberley Ryan, Mark Appleyard, Florian Grimpen","doi":"10.1007/s12029-025-01313-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Small bowel (SB) capsule endoscopy (CE) is a well-established investigation for suspected SB pathology, but little research has evaluated the diagnostic miss rate of SB cancer. This Australian study sought to assess the risk of developing SB cancer within 36 months of a cancer-negative CE (PCSBC-3Y) using a novel root-cause analysis (RCA) method.</p><p><strong>Methods: </strong>Using a prospective CE database and data linkage with a population-based state cancer registry, the PCSBC-3Y rate was evaluated in consecutive patients undergoing CE between 2007 and 2019. SB cancers diagnosed or suspected from CE were defined as 'detected cancers', whilst those diagnosed within 36 months of a negative CE were defined as 'missed cancers'. Descriptive statistics summarised characteristics for all diagnosed SB cancers. All PCSBC-3Y cases were evaluated by RCA.</p><p><strong>Results: </strong>A total of 20 patients were diagnosed with SB cancer within 36 months of CE, comprising of 18 detected cancers and two missed cancers. The overall PCSBC-3Y rate was 10% (95% CI 2.6-28.7%). The two missed cancers included one jejunal gastrointestinal stromal tumour and one duodenal adenocarcinoma. RCA revealed both missed cancers to be unavoidable, as the SB was normal on two retrospective reviews of the CE video recordings.</p><p><strong>Conclusion: </strong>This study introduces the concept of measuring the PCSBC-3Y rate and a novel algorithm of RCA. In our quaternary referral CE cohort, the PCSBC-3Y rate was 10%. A subsequent RCA suggested that the two missed cancers were unavoidable.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"190"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450118/pdf/","citationCount":"0","resultStr":"{\"title\":\"Post Capsule Endoscopy Small Bowel Cancer Rate-An Australian Data Linkage Analysis.\",\"authors\":\"Paris Hoey, Naeman Goetz, Kimberley Ryan, Mark Appleyard, Florian Grimpen\",\"doi\":\"10.1007/s12029-025-01313-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Small bowel (SB) capsule endoscopy (CE) is a well-established investigation for suspected SB pathology, but little research has evaluated the diagnostic miss rate of SB cancer. This Australian study sought to assess the risk of developing SB cancer within 36 months of a cancer-negative CE (PCSBC-3Y) using a novel root-cause analysis (RCA) method.</p><p><strong>Methods: </strong>Using a prospective CE database and data linkage with a population-based state cancer registry, the PCSBC-3Y rate was evaluated in consecutive patients undergoing CE between 2007 and 2019. SB cancers diagnosed or suspected from CE were defined as 'detected cancers', whilst those diagnosed within 36 months of a negative CE were defined as 'missed cancers'. Descriptive statistics summarised characteristics for all diagnosed SB cancers. All PCSBC-3Y cases were evaluated by RCA.</p><p><strong>Results: </strong>A total of 20 patients were diagnosed with SB cancer within 36 months of CE, comprising of 18 detected cancers and two missed cancers. The overall PCSBC-3Y rate was 10% (95% CI 2.6-28.7%). The two missed cancers included one jejunal gastrointestinal stromal tumour and one duodenal adenocarcinoma. RCA revealed both missed cancers to be unavoidable, as the SB was normal on two retrospective reviews of the CE video recordings.</p><p><strong>Conclusion: </strong>This study introduces the concept of measuring the PCSBC-3Y rate and a novel algorithm of RCA. In our quaternary referral CE cohort, the PCSBC-3Y rate was 10%. A subsequent RCA suggested that the two missed cancers were unavoidable.</p>\",\"PeriodicalId\":15895,\"journal\":{\"name\":\"Journal of Gastrointestinal Cancer\",\"volume\":\"56 1\",\"pages\":\"190\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450118/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Gastrointestinal Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12029-025-01313-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12029-025-01313-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：小肠（SB）胶囊内镜（CE）是一种成熟的对疑似SB病理的检查方法，但很少有研究评估SB癌的诊断漏诊率。这项澳大利亚研究试图使用一种新的根本原因分析（RCA）方法，评估癌症阴性CE （PCSBC-3Y）后36个月内发生SB癌的风险。方法：使用前瞻性CE数据库和基于人群的州癌症登记处的数据链接，评估2007年至2019年连续接受CE治疗的患者的PCSBC-3Y率。经诊断或疑似由CE引起的SB癌症被定义为“已发现的癌症”，而在CE阴性后36个月内被诊断出的癌症被定义为“未发现的癌症”。描述性统计总结了所有诊断的SB癌的特征。所有PCSBC-3Y病例均行RCA评估。结果：20例患者在CE术后36个月内被诊断为SB癌，其中18例被发现，2例未被发现。总体PCSBC-3Y发生率为10% （95% CI 2.6-28.7%）。2例未发现的肿瘤包括1例空肠胃肠道间质瘤和1例十二指肠腺癌。RCA显示两种遗漏的癌症是不可避免的，因为在两次CE录像的回顾性回顾中，SB是正常的。结论：本研究介绍了PCSBC-3Y速率测量的概念和一种新的RCA算法。在我们的四级转诊CE队列中，PCSBC-3Y率为10%。随后的RCA表明，这两种遗漏的癌症是不可避免的。
Post Capsule Endoscopy Small Bowel Cancer Rate-An Australian Data Linkage Analysis.
Purpose: Small bowel (SB) capsule endoscopy (CE) is a well-established investigation for suspected SB pathology, but little research has evaluated the diagnostic miss rate of SB cancer. This Australian study sought to assess the risk of developing SB cancer within 36 months of a cancer-negative CE (PCSBC-3Y) using a novel root-cause analysis (RCA) method.
Methods: Using a prospective CE database and data linkage with a population-based state cancer registry, the PCSBC-3Y rate was evaluated in consecutive patients undergoing CE between 2007 and 2019. SB cancers diagnosed or suspected from CE were defined as 'detected cancers', whilst those diagnosed within 36 months of a negative CE were defined as 'missed cancers'. Descriptive statistics summarised characteristics for all diagnosed SB cancers. All PCSBC-3Y cases were evaluated by RCA.
Results: A total of 20 patients were diagnosed with SB cancer within 36 months of CE, comprising of 18 detected cancers and two missed cancers. The overall PCSBC-3Y rate was 10% (95% CI 2.6-28.7%). The two missed cancers included one jejunal gastrointestinal stromal tumour and one duodenal adenocarcinoma. RCA revealed both missed cancers to be unavoidable, as the SB was normal on two retrospective reviews of the CE video recordings.
Conclusion: This study introduces the concept of measuring the PCSBC-3Y rate and a novel algorithm of RCA. In our quaternary referral CE cohort, the PCSBC-3Y rate was 10%. A subsequent RCA suggested that the two missed cancers were unavoidable.
期刊介绍：
The Journal of Gastrointestinal Cancer is a multidisciplinary medium for the publication of novel research pertaining to cancers arising from the gastrointestinal tract.The journal is dedicated to the most rapid publication possible.The journal publishes papers in all relevant fields, emphasizing those studies that are helpful in understanding and treating cancers affecting the esophagus, stomach, liver, gallbladder and biliary tree, pancreas, small bowel, large bowel, rectum, and anus. In addition, the Journal of Gastrointestinal Cancer publishes basic and translational scientific information from studies providing insight into the etiology and progression of cancers affecting these organs. New insights are provided from diverse areas of research such as studies exploring pre-neoplastic states, risk factors, epidemiology, genetics, preclinical therapeutics, surgery, radiation therapy, novel medical therapeutics, clinical trials, and outcome studies.In addition to reports of original clinical and experimental studies, the journal also publishes: case reports, state-of-the-art reviews on topics of immediate interest or importance; invited articles analyzing particular areas of pancreatic research and knowledge; perspectives in which critical evaluation and conflicting opinions about current topics may be expressed; meeting highlights that summarize important points presented at recent meetings; abstracts of symposia and conferences; book reviews; hypotheses; Letters to the Editors; and other items of special interest, including:Complex Cases in GI Oncology: This is a new initiative to provide a forum to review and discuss the history and management of complex and involved gastrointestinal oncology cases. The format will be similar to a teaching case conference where a case vignette is presented and is followed by a series of questions and discussion points. A brief reference list supporting the points made in discussion would be expected.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
